MimiVax receives fast-track designation for brain cancer therapy

MimiVax LLC, which spun off from Roswell Park Comprehensive Cancer Center, has been developing its SurVaxM therapy for several years for treatment of glioblastoma.

Previous Blue Water Biotech names new CEO, CFO as company faces dual Nasdaq delisting notices
Next State warns of 'potentially fraudulent' mailer seeking cannabis license applicants